Theratechnologies Q3 Earnings Lags Consensus As Trogarzo Sales Decline


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


  • Theratechnologies Inc (NASDAQ:THTXreported Q3 sales of $17.85 million, +27% Y/Y propelled by higher Egrifta sales of $11.22 million, +64%. The revenue missed the consensus of $19.66 million.
  • Trogarzo sales declined 8% to $6.63 million on lower unit sales as patients refrained from visiting their physicians. Competitive pressures and higher rebates also impacted the sales.
  • It posted a net loss of $(0.10) for the quarter compared to $(0.09) a year ago, missing the consensus loss of $(0.07).
  • The Company used $(3.13) million in operating cash flow.
  • Price Action: THTX shares closed lower by 0.14% at $3.50 on Tuesday.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: EarningsNewsPenny StocksSmall CapTechBriefs